Neri, Dario, Prof. Dr.
Born in Rome (Italy) on 1 May 1963, Dario Neri studied Chemistry at the Scuola Normale Superiore of Pisa, graduating with a thesis on the synthesis and characterization of complex polyunsaturated secondary metabolites, isolated from higher plants. He earned his doctorate in Chemistry under the supervision of Prof. Dr. Kurt Wüthrich at the Institute of Molecular Biology and Biophysics of the ETH Zürich in 1992, receiving the Silver Medal of ETH Zürich for his dissertation.
With an EU Bridge Bursary, Dario Neri worked from 1992 until 1996 at the Cambridge Centre for Protein Engineering, Medical Research Council Centre, under the supervision of Sir Gregory Winter. He has now been a Professor at the ETH Zurich since 1996.
The research of the group Neri focuses on the engineering of therapeutic antibodies for the treatment of cancer and of chronic inflammatory conditions. Other research activities include the development of DNA-encoded chemical libraries and of small molecule-drug conjugates. Furthermore, the group uses mass spectrometry methodologies for the discovery of vascular markers of disease and for HLA peptidome analysis.
Dario Neri is a co-founder of Philogen (www.philogen.com), a Swiss-Italian Biotech company which has brought five antibody products to Phase II clinical trials for the therapy of cancer and of rheumatoid arthritis.
Dario Neri has published over 300 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the 2011 Prix Mentzer of the French Society for Medicinal Chemistry (RICT) and of the Phoenix Award 2014 for Pharmacology and Clinical Pharmacy.